Kalbe (IDX:KLBF)

Executive Summary

Kalbe is Indonesia's leading integrated healthcare group, with a strong presence in pharmaceuticals, nutraceuticals, and consumer health. The company leverages a robust R&D platform to develop innovative biologics, biosimilars, and specialty medicines across oncology, immunology, cardiovascular, metabolic, and infectious diseases. With extensive manufacturing capacity and a wide distribution network across Southeast Asia, Kalbe is well-positioned to capture growing demand in emerging markets. As a publicly traded entity (IDX:KLBF), the company benefits from a commercial-stage revenue base, a diversified product portfolio, and strategic partnerships that support its long-term growth trajectory. Kalbe's future growth is driven by the expansion of its biosimilar pipeline, potential regulatory approvals for novel therapies, and increased penetration into regional markets. The company is advancing several high-value biosimilars in oncology and immunology, targeting both domestic and export markets. Additionally, ongoing investments in R&D and manufacturing capabilities, along with strategic collaborations, are expected to accelerate product launches. Key near-term catalysts include the filing or approval of a major biosimilar, the initiation of a new clinical trial, and the expansion of its distribution network into new Southeast Asian countries. These factors underpin Kalbe's ability to sustain its leadership and deliver shareholder value.

Upcoming Catalysts (preview)

• Q3 2026Biosimilar trastuzumab approval or launch in Indonesia80% success
• Q4 2026Partnership or licensing deal for a novel oncology therapy60% success
• Q3 2026Expansion into Philippines or Vietnam distribution network70% success